1Ivanovic D, Medenica M, Jancic B, et al. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules [ J ]. Journal of Chromatography B,2004,800 : 253 - 8.
2Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 Acid Glycoprotein Binds to Imatinib ( STI571 ) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients. [ J]. Clinical Cancer Research,2003,9 ( 2 ) : 625 - 32.
3Hamada A, Miyano H, Watanabe H, et al. Interaction Of Imatinib Mesilate with Human P-Glycoprotein [ J]. The Journal Of Pharmacology And Experimental Therapeutics,2003,307 (2) : 824 - 8.
4Vamvakopoulos JE, Petrov L, Aavik S, et al. Synergistic Suppression of Rat Neointimal Hyperplasia by Rapamyciu and Imatinib Mesylate : Implications for the Prevention of Accelerated Arteriosclerosis [J]. J Vasc Res,2006 43:184 -92.
5Rosasco MA, Moyano MA, MTPizzorno MT, et al. Validation of an HPLC Method for the Determination of Imatinib Mesylate in Pharmaceutical Dosage[ J]. Journal of Liquid Chromatography & Related Technologies,2005,28 (20) :3283 - 92.
6Oostendorp RL, Beijnen JH, Schellensi HM, et al. Determination Of Imatinib Mesylate And Its Main Metabolite (CGP74588) In Human Plasma And Murine Specimens By Ion-Pairing Reversed-Phase High-Performance Liquid Chromatography [ J ]. Biomed Chromatogr Published Online,2007,27 ( 3 ) : 34 - 6.
7Mathur RVT,Agarwal NK. Development and Validation of A Simple Liquid Chromatographic Method With Ultraviolet Detection For The Determination Of Imatinib In Biological Samples[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2004,804(2) :431 -7.
8Widmer N, Beguin A, Rochat B, et al. Determination Of lmatinib (Gleevec ) In Human Plasma By Solid-Phase Extraction-Liquid Chromatography-Ultraviolet Absorbance Detection [ J ]. Journal of Chromatography,2004,803:285 - 92.
9Rodriguez Flores J, Berzas JJ, Castaneda G, et al. Direct and fast capillary zone electrophoretic method for the Determination of Gleevec and its main metabolite in human urine [J].Journal of Chromatography B,2003,794:381 - 8.
10Gschwind H, Pfaar U, Waldmeier F, et al. Metabolism And Disposition Of Imatinib Mesylate In Healthy Volunteers [J]. American Society for Pharmacology and Experimental Therapeutics , 2006,33 (10) :1503 -12.
6Szczepek WJ, Kosmaci' nska B, Bielejewska A, et al. Identification of imatinib mesylate degradation products obtained under stress condi- tions. J Pharm Biomed Anal ,2007,43 ( 5 ) : 1682.
7Medenica M,Jancic B,Ivanovic D,et al. Experimental design in re- versed - phase high - performance liquid chromatographic analysis of imatinib mesylate and its impurity. J Chromatogr, 2004, A ( 1031 ) :243.
8Ivanovic D, Medenica M, Jancic B, et al. Reversed -phase liquid chromatography analysis of imatinibmesylate and impurity product in Glivec capsules. J Chromatogr,2004, B (800) :253.
9Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr - Abl positive ceils [ J ]. Nat Med, 1996,2 ( 5 ) :561 - 566.
